Value of P-glycoprotein and clinicopathologic factors as the basis for new treatment strategies in high-grade osteosarcoma of the extremities.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Journal of Clinical Oncology

• Publication date

  2003-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2003.03.144PMID 12560446
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The Scandinavian Sarcoma Group experience

  2004cited by this paper
• Neoadjuvant Chemotherapy for High Grade Osteosarcoma of the Extremities: Long-Term Results for Patients Treated According to the Rizzoli IOR/OS-3b Protocol

  2001cited by this paper
• Predictive factors of disease-free survival for non-metastatic osteosarcoma of the extremity: an analysis of 300 patients treated at the Rizzoli Institute.

  2001cited by this paper
• P-Glycoprotein Levels Predict Poor Outcome in Patients With Osteosarcoma

  2000cited by this paper
• The co-expression of p53 protein and P-glycoprotein is correlated to a poor prognosis in osteosarcoma

  2000cited by this paper
• Osteosarcomas and other cancers of bone.

  2000cited by this paper
• Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the istituto ortopedico rizzoli according to the istituto ortopedico rizzoli/osteosarcoma-2 protocol: an updated report.

  2000cited by this paper
• P‐glycoprotein expression in osteosarcoma: A basis for risk‐adapted adjuvant chemotherapy

  1999cited by this paper
• Nonmetastatic Osteosarcoma of the Extremity: Results of a Neoadjuvant Chemotherapy Protocol (IOR/OS-3) with High-dose Methotrexate, Intraarterial or Intravenous Cisplatin, Doxorubicin, and Salvage Chemotherapy Based on Histologic Tumor Response

  1999cited by this paper
• Chemotherapy in osteosarcomaThe Scandinavian Sarcoma Group experience

  1999cited by this paper
• Relationship between P-glycoprotein expression and p53 status in high-grade osteosarcoma.

  1999cited by this paper
• Expression of HER2/erbB-2 correlates with survival in osteosarcoma.

  1999cited by this paper
• The expression of P-glycoprotein is causally related to a less aggressive phenotype in human osteosarcoma cells

  1999cited by this paper
• Bone and Soft Tissue Tumors

  1999cited by this paper
• Long-term results of the co-operative German-Austrian-Swiss osteosarcoma study group's protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs.

  1998cited by this paper
• Osteosarcoma and other bone cancers.

  1998cited by this paper
• Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup.

  1997cited by this paper
• P-glycoprotein expression: critical determinant in the response to osteosarcoma chemotherapy.

  1997cited by this paper
• The role of chemotherapy in the management of non-metastatic operable extremity osteosarcoma.

  1997cited by this paper
• P-glycoprotein expression in high grade central osteosarcoma and normal bone cells. An immunohistochemical study.

  1997cited by this paper
• On the current management of osteosarcoma. A critical evaluation and a proposal for a modified treatment strategy.

  1997cited by this paper
• Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children's Cancer Group.

  1997cited by this paper
• Influence of methotrexate dose intensity on outcome of patients with high grade osteogenic osteosarcoma: Analysis of the literature

  1996cited by this paper
• Tumor size and prognosis in aggressively treated osteosarcoma.

  1996cited by this paper
• ErbB‐2 expression is correlated with poor prognosis for patients with osteosarcoma

  1996cited by this paper
• Multidrug resistance and malignancy in human osteosarcoma.

  1996cited by this paper
• Analysis of P-glycoprotein expression in osteosarcoma.

  1995cited by this paper
• Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome.

  1995cited by this paper
• Prognostic factors in osteosarcoma: a critical review.

  1994cited by this paper
• Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremities. Results in 164 patients preoperatively treated with high doses of methotrexate followed by cisplatin and doxorubicin

  1993cited by this paper
• A comparison of two short intensive adjuvant chemotherapy regimens in operable osteosarcoma of limbs in children and young adults: the first study of the European Osteosarcoma Intergroup.

  1992cited by this paper
• Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience.

  1992cited by this paper
• Distribution of multidrug resistance-associated P-glycoprotein in normal and neoplastic human tissue

  1990cited by this paper
• Distribution of multi-drug resistance-associated P-glycoprotein in normal and neoplastic human tissues. Analysis with 3 monoclonal antibodies recognizing different epitopes of the P-glycoprotein molecule.

  1990cited by this paper
• Immunoproliferative small-intestinal disease. An immunohistochemical study.

  1989cited by this paper
• Osteosarcoma: fifteen years later.

  1985cited by this paper

• Is There a Role for Mifamurtide in Nonmetastatic High-Grade Osteosarcoma? Results From the Italian Sarcoma Group (ISG/OS-2) and Spanish Sarcoma Group (GEIS-33) Trials

  2025cites this paper
• Prognostic Factors in Newly Diagnosed High‐Grade Osteosarcoma—A Systematic Review

  2025cites this paper
• Genomic profiling of a collection of patient-derived xenografts and cell lines identified ixabepilone as an active drug against chemo-resistant osteosarcoma

  2025cites this paper
• Tumor immune microenvironment-associated prognostic and mifamurtide-response gene signatures for localized osteosarcoma: a correlative study of the ISG/OS2 trial.

  2025cites this paper
• Pharmacogenetics of Neoadjuvant MAP Chemotherapy in Localized Osteosarcoma: A Study Based on Data from the GEIS-33 Protocol

  2024cites this paper
• Strategies to Overcome Resistance to Immune-Based Therapies in Osteosarcoma

  2023cites this paper
• Genomic and proteomic profiling of osteosarcoma

  2022cites this paper
• The strategy and clinical relevance of in vitro models of MAP resistance in osteosarcoma: a systematic review

  2022influential citation
• Phase 2 study for nonmetastatic extremity high‐grade osteosarcoma in pediatric and adolescent and young adult patients with a risk‐adapted strategy based on ABCB1/P‐glycoprotein expression: An Italian Sarcoma Group trial (ISG/OS‐2)

  2022cites this paper
• Exosomal Long Non-Coding RNA ANCR Mediates Drug Resistance in Osteosarcoma

  2022cites this paper
• Impact of ABC Transporters in Osteosarcoma and Ewing’s Sarcoma: Which Are Involved in Chemoresistance and Which Are Not?

  2021cites this paper
• Drug Resistance in Osteosarcoma: Emerging Biomarkers, Therapeutic Targets and Treatment Strategies

  2021cites this paper
• Mechanisms of Resistance to Conventional Therapies for Osteosarcoma

  2021cites this paper
• Pleiotropic activities of nitric oxide-releasing doxorubicin on P-glycoprotein/ABCB1

  2020cites this paper
• Long-Term Follow-up of a Randomized Study of Oral Etoposide versus Viscum album Fermentatum Pini as Maintenance Therapy in Osteosarcoma Patients in Complete Surgical Remission after Second Relapse

  2020cites this paper
• Histological and Immunohistochemical Prognostic Factors inPaediatric Osteosarcoma - A Retrospective Study

  2020cites this paper
• Diagnosis of Musculoskeletal Tumors and Tumor-like Conditions: Clinical, Radiological and Histological Correlations - The Rizzoli Case Archive

  2020cites this paper
• ABCA1/ABCB1 Ratio Determines Chemo- and Immune-Sensitivity in Human Osteosarcoma

  2020cites this paper
• Small Nucleolar RNAs Determine Resistance to Doxorubicin in Human Osteosarcoma

  2020cites this paper
• Hyaluronated liposomes containing H2S-releasing doxorubicin are effective against P-glycoprotein-positive/doxorubicin-resistant osteosarcoma cells and xenografts.

  2019cites this paper
• Biology of Osteosarcomas

  2019cites this paper
• A new LDL-masked liposomal doxorubicin overcomes drug resistance in osteosarcoma

  2019cites this paper
• An update on emerging drugs in osteosarcoma: towards tailored therapies?

  2019cites this paper
• Study of the interactions between CD99, immunologic microenvironment and microRNAs and their prognostic significance in human osteosarcoma

  2018cites this paper
• Efflux inhibition by IWR‐1‐endo confers sensitivity to doxorubicin effects in osteosarcoma cells

  2018cites this paper
• Novel anthracyclines with enhanced immunogenic effects against drug resistant osteosarcoma cells

  2018cites this paper
• Endoplasmic reticulum-targeting doxorubicin: a new tool effective against doxorubicin-resistant osteosarcoma

  2018cites this paper
• Ectopic Production of Β-hCG and Loss of P 16 as a Predictor of Outcome in Patients with Newly Diagnosed Osteosarcoma

  2016cites this paper
• Methanolic Extract of Pien Tze Huang Induces Apoptosis Signaling in Human Osteosarcoma MG63 Cells via Multiple Pathways

  2016cites this paper
• Mitochondria-Targeted Doxorubicin: A New Therapeutic Strategy against Doxorubicin-Resistant Osteosarcoma

  2016cites this paper
• Targeting ABCB1 (MDR1) in multi-drug resistant osteosarcoma cells using the CRISPR-Cas9 system to reverse drug resistance

  2016cites this paper
• Genome Analysis of Osteosarcoma Progression Samples Identifies FGFR1 Overexpression as a Potential Treatment Target and CHM as a Candidate Tumor Suppressor Gene

  2016cites this paper
• The pharmacogenomics of osteosarcoma

  2016cites this paper
• p16 expression as a prognostic and predictive marker in high-grade localized osteosarcoma of the extremities: an analysis of 357 cases.

  2016cites this paper
• MiR-100 Inhibits Osteosarcoma Cell Proliferation, Migration, and Invasion and Enhances Chemosensitivity by Targeting IGFIR

  2016cites this paper
• Targeting ABCB1 and ABCC1 with their Specific Inhibitor CBT-1® can Overcome Drug Resistance in Osteosarcoma.

  2016cites this paper
• An update on chemotherapy for osteosarcoma

  2015cites this paper
• Excision repair cross‐complementation group 1 protein expression predicts survival in patients with high‐grade, non‐metastatic osteosarcoma treated with neoadjuvant chemotherapy

  2015cites this paper
• Gene and proteomic profiling of osteosarcoma

  2015cites this paper
• ercc1 protein expression predicts survival in patients with high-grade, non-metastatic osteosarcoma treated with neoadjuvant chemotherapy Short running title: ercc1 clinical impact in high-grade osteosarcoma

  2015cites this paper
• Advances in emerging drugs for osteosarcoma

  2015cites this paper
• Biology of Osteosarcoma

  2014cites this paper
• Review of the molecular pathogenesis of osteosarcoma.

  2014cites this paper
• An aza-macrocycle containing maltolic side-arms (maltonis) as potential drug against human pediatric sarcomas

  2014cites this paper
• Pien Tze Huang induces apoptosis in multidrug‑resistant U2OS/ADM cells via downregulation of Bcl‑2, survivin and P-gp and upregulation of Bax.

  2014cites this paper
• Metformin as an Adjuvant Drug against Pediatric Sarcomas: Hypoxia Limits Therapeutic Effects of the Drug

  2013cites this paper
• MRP1 Overexpression Determines Poor Prognosis in Prospectively Treated Patients with Localized High-Risk Soft Tissue Sarcoma of Limbs and Trunk Wall: An ISG/GEIS Study

  2013cites this paper
• P16 expression predicts necrotic response among patients with osteosarcoma receiving neoadjuvant chemotherapy.

  2012cites this paper
• Osteosarcoma of jaws

  2012cites this paper
• Pirarubicin inhibits multidrug-resistant osteosarcoma cell proliferation through induction of G2/M phase cell cycle arrest

  2012cites this paper
• Current concepts on pathogenesis and biology of metastatic osteosarcoma tumors.

  2011cites this paper
• YY1 overexpression is associated with poor prognosis and metastasis-free survival in patients suffering osteosarcoma

  2011cites this paper
• Nucleotide excision repair gene variants and association with survival in osteosarcoma patients treated with neoadjuvant chemotherapy

  2011cites this paper
• P-Glycoprotein Expression, Tumor Weight, Age, and Relapse in Patients with Stage I and II Favorable-Histology Wilms’ Tumor

  2011cites this paper
• Chapter 17 – Immunohistology of Pediatric Neoplasms

  2011cites this paper
• A novel gene P28GANK confers multidrug resistance by modulating the expression of MDR-1, Bcl-2, and bax in osteosarcoma cells

  2010cites this paper
• Emerging drugs for high-grade osteosarcoma

  2010cites this paper
• Molecularly targeted therapy for osteosarcoma: Where do we go from here?

  2010cites this paper
• Biomarkers in Osteosarcoma.

  2009cites this paper
• Mechanisms of gene amplification and evidence of coamplification in drug‐resistant human osteosarcoma cell lines

  2009cites this paper
• Bone marrow micrometastases studied by an immunomagnetic isolation procedure in extremity localized non-metastatic osteosarcoma patients.

  2009cites this paper
• Human osteosarcoma xenografts and their sensitivity to chemotherapy

  2009cites this paper
• The treatment of nonmetastatic high grade osteosarcoma of the extremity: review of the Italian Rizzoli experience. Impact on the future.

  2009cites this paper
• Osteosarcoma: is age an issue?

  2009cites this paper
• Prognostic Effect of Diaphyseal Location in Osteosarcoma: A Cohort Case–Control Study at a Single Institute

  2009cites this paper
• Clinical Significance of P-Glycoprotein Immunohistochemistry and Histomorphologic Factors in Patients with Osteosarcoma

  2009cites this paper
• XIAP expression and its predictive significance of prognosis in stage IIB osteosarcomas

  2008cites this paper
• An examination of the efficacy of the 8 cm maximal tumor diameter cutoff for the subdivision of AJCC stage II osteosarcoma patients

  2008cites this paper
• Clinical impact of the methotrexate resistance-associated genes C-MYC and dihydrofolate reductase (DHFR) in high-grade osteosarcoma.

  2008cites this paper
• Initial tumor size predicts histologic response and survival in localized osteosarcoma patients

  2008cites this paper
• Multiple drug resistance in osteogenic sarcoma: INT0133 from the Children's Oncology Group.

  2007cites this paper
• GLICOPROTEÍNAP53 EN OSTEOSARCOMAS HUMANOS

  2007cites this paper
• Estudio de la expresión de la pglicoproteína y del p53 en osteosarcomas humanos

  2007cites this paper
• Ezrin Expression Predicts Survival in Stage IIB Osteosarcomas

  2007cites this paper
• Epidermal Growth Factor Receptor Expression in High-Grade Osteosarcomas Is Associated with a Good Clinical Outcome

  2007cites this paper
• Caveolin-1 reduces osteosarcoma metastases by inhibiting c-Src activity and met signaling.

  2007cites this paper
• Livin and Bcl-2 expression in high-grade osteosarcoma

  2007influential citation
• Prognostic value of P-glycoprotein in high-grade osteosarcoma.

  2007cites this paper
• Osteosarcoma: basic science and clinical implications.

  2006cites this paper
• Staging of Primary Malignancies of Bone

  2006cites this paper
• KAI-1 Expression in Pediatric High-Grade Osteosarcoma

  2006cites this paper
• Anticancer effects of zoledronic acid against human osteosarcoma cells

  2006cites this paper
• Influence of neoadjuvant chemotherapy on proliferation, apoptosis and multi-drug resistance in osteosarcoma cells

  2006cites this paper
• Chemotherapy resistance in osteosarcoma: current challenges and future directions

  2006cites this paper
• STUDIO DEI MECCANISMI DELLA FARMACORESISTENZA NELL'OSTEOSARCOMA UMANO PER LA PIANIFICAZIONE DI NUOVE STRATEGIE TERAPEUTICHE

  2006cites this paper
• May P-glycoprotein status be used to stratify high-grade osteosarcoma patients? Results from the Italian/Scandinavian Sarcoma Group 1 treatment protocol.

  2006cites this paper
• Immunohistology of Pediatric Neoplasms

  2006cites this paper
• Fatores clínicos e biológicos para recidivas em tumores de Wilms

  2005cites this paper
• Hematogenous Micrometastases in Osteosarcoma Patients

  2005cites this paper
• Metastatic osteosarcoma at diagnosis

  2005cites this paper
• 4-Demethoxy-3'-deamino-3'-aziridinyl-4'-methylsulphonyl-daunorubicin (PNU-159548): a promising new candidate for chemotherapeutic treatment of osteosarcoma patients.

  2005cites this paper
• Prognostic and therapeutic relevance of HER2 expression in osteosarcoma and Ewing's sarcoma.

  2005cites this paper
• Treatment effects in pediatric soft tissue and bone tumors: practical considerations for the pathologist.

  2005cites this paper
• Biology and therapy of malignant solid tumors in childhood.

  2005cites this paper
• HematogenousMicrometastases in Osteosarcoma Patients

  2005cites this paper
• Análise imunohistoquímica do osteossarcoma em pacientes com e sem metástases e sua correlação prognóstica

  2005cites this paper
• Analysis of dihydrofolate reductase and reduced folate carrier gene status in relation to methotrexate resistance in osteosarcoma cells.

  2004cites this paper
• Role of MMP-9 and its tissue inhibitor TIMP-1 in human osteosarcomaFindings in 42 patients followed for 1–16 years

  2004cites this paper
• Tumor size as a predictor of outcome in pediatric non‐metastatic osteosarcoma of the extremity

  2004cites this paper
• Structure-activity analysis of taxane-based broad-spectrum multidrug resistance modulators.

  2004cites this paper